Stocks Comparison
DocGo vs GeneDx: revenue, profit, margins and growth compared
DocGo brought in $322.2M of revenue in fiscal 2025, GeneDx $427.5M in fiscal 2025. Revenue changed by -47.7% at DocGo and +40.0% at GeneDx on the year before, so GeneDx grew faster. DocGo kept -56.6% of its revenue as net profit, GeneDx -4.9%. Free cash flow was $29.9M at DocGo and $14.3M at GeneDx.
Side by side, latest fiscal year
| DCGO | WGS | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $322.2M | $427.5M |
| Revenue growth | -47.7% | +40.0% |
| Net income | -$182.4M | -$21M |
| Net margin | -56.6% | -4.9% |
| Free cash flow | $29.9M | $14.3M |
| Free cash flow margin | 9.3% | 3.3% |
| Earnings per share (diluted) | -$1.84 | -$0.73 |
| Cash | $51M | $105M |
| Debt | $235.6K | $54.5M |
| Price to earnings | n/a | n/a |
| Market value | $34.1M | $2.6B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #217 of 523 · Health care | #199 of 523 · Health care |
Over the years
Questions about DocGo and GeneDx
Which is bigger by revenue, DocGo or GeneDx?
GeneDx is bigger by revenue: $427.5M in fiscal 2025, against $322.2M for DocGo in fiscal 2025.
Which keeps more of its revenue as profit, DocGo or GeneDx?
DocGo had a net margin of -56.6% in fiscal 2025; GeneDx had -4.9% in fiscal 2025.
Which grew revenue faster, DocGo or GeneDx?
In their latest fiscal years revenue changed by -47.7% at DocGo and +40.0% at GeneDx.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.